Stock Price Quote

AMRUTANJAN HEALTH CARE LTD.

NSE : AMRUTANJANBSE : 590006ISIN CODE : INE098F01031Industry : Pharmaceuticals & DrugsHouse : Amrutanjan
BSE743.15-0.35 (-0.05 %)
PREV CLOSE ( ) 743.50
OPEN PRICE ( ) 745.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 285
TODAY'S LOW / HIGH ( )740.00 748.60
52 WK LOW / HIGH ( )556.05 802.6
NSE740.55-4.4 (-0.59 %)
PREV CLOSE( ) 744.95
OPEN PRICE ( ) 744.95
BID PRICE (QTY) 740.55 (63)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4921
TODAY'S LOW / HIGH( ) 737.30 755.00
52 WK LOW / HIGH ( )563.9 804
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 09-09 1936
Management Info
S Sambhu Prasad - Chairman S Sambhu Prasad - Managing Director
Registered Office

Address New 103 (Old 42-45),Luz Church Road,Mylapore,
Chennai,
Tamil Nadu-600004

Phone 044- 24994465 / 24669000 / 18004254545

Email customercare@amrutanjan.com

Website www.amrutanjan.com

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE, Chennai

NEWS

08May Amrutanjan Health Care informs about d
Amrutanjan Health Care has informed that the exchange has received the d..
07May Amrutanjan Health Care informs about d
Amrutanjan Health Care has informed that it enclosed disclosure under Re..
04Mar Amrutanjan Health Care informs about d
Amrutanjan Health Care has informed that it enclosed disclosure under Re..
04Mar Amrutanjan Health Care informs about d
Amrutanjan Health Care has informed that it enclosed disclosure under Re..
04Mar Amrutanjan Health Care informs about d
Amrutanjan Health Care has informed that it enclosed disclosure under Re..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit174.51398.34
Gross Profit 237.08 536.45
Operating Profit 253.38589.34
Net Sales 1169.943796.36

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

MUTUAL FUNDS/UTI 6.79%
PROMOTERS 50.59%
NON-INSTITUTION 40.74%
FI/BANKS/INSURANCE 0.09%
GOVERNMENT 0%
FII 0%

About Amrutanjan Health Care Ltd.

Amrutanjan Health Care Ltd. was incorporated in the year 1936. Its today's share price is 743.15. Its current market capitalisation stands at Rs 2148.49 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3796.36 Cr and Total Income of Rs.3941.78 Cr. The company's management includes M Srinivasan, Ramaa Prabhakar Arikirevula, Meenalochani Raghunathan, S Muralidharan, Raja Venkataraman, G Raghavan, S Sambhu Prasad, S Sambhu Prasad.

It is listed on the BSE with a BSE Code of 590006 , NSE with an NSE Symbol of AMRUTANJAN and ISIN of INE098F01031. It's Registered office is at New 103 (Old 42-45),Luz Church Road,MylaporeChennai-600004, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, PS Subramania Iyer & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.